Recruiting PHASE3 INTERVENTIONAL 2-arm NCT07188558

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy (PiNACLE-H2H)

A Phase 3 Randomized Controlled Trial of Rondecabtagene Autoleucel , an Autologous, Dual-targeting CD19/CD20 CAR T-Cell Product Candidate, Vs. Investigator's Choice of CD19 CAR T-Cell Therapy in Patients With Relapsed or Refractory Large B-Cell Lymphoma in the Second-line Setting

Sponsor: Lyell Immunopharma, Inc.

Conditions Diffuse Large B Cell Lymphoma (DLBCL) Diffuse Large B Cell Lymphoma Refractory Diffuse Large B Cell Lymphoma Relapsed Large B-cell Lymphoma Lymphoma, B-Cell Non-Hodgkin Lymphoma Non-Hodgkin Lymphoma Refractory/ Relapsed Refractory Non-Hodgkin Lymphoma Relapsed Non-Hodgkin Lymphoma

Interventions axicabtagene ciloleucel lisocabtagene maraleucel rondecabtagene autoleucel

Updated 4 times since 2025 Last updated: Mar 2, 2026 Started: Jan 12, 2026 Primary completion: Dec 31, 2029 Completion: Jan 31, 2032

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Diffuse Large B Cell Lymphoma (DLBCL) and Diffuse Large B Cell Lymphoma Refractory and is currently actively recruiting participants. Lyell Immunopharma, Inc. leads this study, which shows 4 recorded versions since 2026 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

4 versions recorded

Mar 2026 — Present [monthly]

Recruiting PHASE3
Feb 2026 — Mar 2026 [monthly]

Recruiting PHASE3
Jan 2026 — Feb 2026 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Oct 2025 — Jan 2026 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Lyell Immunopharma, Inc.

Data source: Lyell Immunopharma, Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Austin, United States , Buffalo, United States , Chicago, United States , Cincinnati, United States , Cleveland, United States , Denver, United States , Durham, United States , Fort Worth, United States and 25 more locations